Danco Laboratories

Last updated
Danco Laboratories
Industry Pharmaceutical
Headquarters New York, United States
Area served
United States
Products mifepristone
Website EarlyOptionPill.com

Danco Laboratories is a pharmaceutical distributor located in midtown Manhattan which distributes the abortifacient drug mifepristone under the brand name Mifeprex. Mifeprex is the only drug distributed by Danco, although the company plans to expand to other drugs in the future.

Contents

Danco is a private company that does not disclose the names of its investors, but stated that "[Investors] included wealthy individuals and foundations that supported abortion rights." [1] [2]

Outside the United States, mifepristone is distributed by the French pharmaceutical company Exelgyn, under the trade name Mifegyne.

History

On 16 May 1994, Roussel-Uclaf announced it was donating without remuneration all rights for medical uses of mifepristone in the United States to the Population Council, [3] which would then sponsor clinical trials for mifepristone between September 1994 and September 1995. [4] In September 1995, The Population Council licensed mifepristone to Danco Laboratories and entered into a manufacturing agreement with Hungarian drug manufacturer Gedeon Richter. [5] In 1996, the US Food and Drug Administration (FDA) conditionally licensed RU-486 for early trimester abortion, pending a resolution on some remaining technical and manufacturing issues. [4]

In 1997, Gideon Richter withdrew from efforts to manufacture mifepristone in the United States following opposition from pro-life groups, which led to Danco filing a breach of contract lawsuit. [6]

On September 28, 2000, Danco Laboratories received approval to distribute mifepristone (under the Mifeprex brand name) from the US Food and Drug Administration (FDA). [7]

Danco had exclusive sales rights in the United States until 2019, when GenBioPro obtained approval to sell a generic version of mifepristone. [8]

See also

Related Research Articles

<span class="mw-page-title-main">Emergency contraception</span> Birth control measures taken after sexual intercourse

Emergency contraception (EC) is a birth control measure, used after sexual intercourse to prevent pregnancy.

<span class="mw-page-title-main">Mifepristone</span> Medication

Mifepristone, also known by its developmental code name RU-486, is a medication typically used in combination with misoprostol to bring about a medical abortion during pregnancy and manage early miscarriage. This combination is 97% effective during the first 63 days of pregnancy. It is also effective in the second trimester of pregnancy. It is taken by mouth.

<span class="mw-page-title-main">Comstock Act of 1873</span> United States anti-obscenity law

The Comstock Act of 1873 is a series of current provisions in Federal law that generally criminalize the involvement of the United States Postal Service, its officers, or a common carrier in conveying obscene matter, crime-inciting matter, or certain abortion-related matter. The Comstock Act is largely codified across title 18 of the United States Code and was enacted beginning in 1872 with the attachment of an extraneous rider to a postal service reconsolidation bill. Amended multiple times since initial enactment, most recently in 1996, the Act is nonetheless often associated with U.S. Postal Inspector and anti-vice activist Anthony Comstock.

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014. The company went public in 1973. Ownership of Ranbaxy changed twice over the course of its history.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

<span class="mw-page-title-main">Barr Pharmaceuticals</span> Former multinational specialty and generic drug manufacturer

Barr Pharmaceuticals was a global specialty and generic drug manufacturer with operations in 30 countries.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

<span class="mw-page-title-main">Roussel Uclaf</span> French pharmaceutical company

Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.

<span class="mw-page-title-main">Zydus Lifesciences</span> Indian multinational pharmaceutical company

Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. The company ranked 100th in the Fortune India 500 list in 2020.

<span class="mw-page-title-main">Birth control in the United States</span>

Birth control in the United States is available in many forms. Some of the forms available at drugstores and some retail stores are male condoms, female condoms, sponges, spermicides, over-the-counter progestin-only contraceptive pills, and over-the-counter emergency contraception. Forms available at pharmacies with a doctor's prescription or at doctor's offices are oral contraceptive pills, patches, vaginal rings, diaphragms, shots/injections, cervical caps, implantable rods, and intrauterine devices (IUDs). Sterilization procedures, including tubal ligations and vasectomies, are also performed.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

A medical abortion, also known as medication abortion or non-surgical abortion, occurs when drugs (medication) are used to bring about an abortion. Medical abortions are an alternative to surgical abortions such as vacuum aspiration or dilation and curettage. Medical abortions are more common than surgical abortions in most places around the world.

<span class="mw-page-title-main">Matthew Kacsmaryk</span> American judge (born 1977)

Matthew Joseph Kacsmaryk is an American lawyer who serves as a United States district judge in the United States District Court for the Northern District of Texas. He was nominated to the position by President Donald Trump in 2017 and sworn in for the position in 2019.

<span class="mw-page-title-main">Aid Access</span> Abortion services provider

Aid Access is a nonprofit organization that provides access to medication abortion by mail to the United States and worldwide. It describes its work as a harm reduction strategy designed to provide safe access to mifepristone and misoprostol for those able to become pregnant in the United States who may not otherwise have access to abortion or miscarriage management services. People are able to manage their own abortion with remote access to a physician and a help-desk for any questions. The website is available in English, Spanish, and Dutch.

As of 2024, abortion is illegal in Indiana. It is only legal in cases involving fatal fetal abnormalities, to preserve the life and physical health of the mother, and in cases of rape or incest up to 10 weeks of pregnancy. Previously abortion in Indiana was legal up to 20 weeks; a near-total ban that was scheduled to take effect on August 1, 2023, was placed on hold due to further legal challenges, but is set to take place, after the Indiana Supreme Court denied an appeal by the ACLU, and once it certifies a previous ruling that an abortion ban doesn't violate the state constitution. In the wake of the 2022 Dobbs Supreme Court ruling, abortion in Indiana remained legal despite Indiana lawmakers voting in favor of a near-total abortion ban on August 5, 2022. Governor Eric Holcomb signed this bill into law the same day. The new law became effective on September 15, 2022. However, on September 22, 2022, Special Judge Kelsey B. Hanlon of the Monroe County Circuit Court granted a preliminary injunction against the enforcement of the ban. Her ruling allows the state's previous abortion law, which allows abortions up to 20 weeks after fertilization with exceptions for rape and incest, to remain in effect.

Food and Drug Administration v. Alliance for Hippocratic Medicine, 602 U.S. 367 (2024), was a United States Supreme Court case to challenge the U.S. Food and Drug Administration (FDA)'s approval of mifepristone, a drug frequently used in medical abortion procedures. The plaintiffs, led by the Alliance for Hippocratic Medicine (AHM), argued that the FDA did not properly approve the use of the drug mifepristone for pregnancy termination under Federal Food, Drug, and Cosmetic Act regulations and asked for an injunction to withdraw the drug's approval, thus removing it from the market. AHM's suit followed the Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization in 2022, which reversed Roe v. Wade and asserted there was no constitutional right to abortion at the federal level, leading conservative states and groups to further restrict abortion access.

Exelgyn is a French pharmaceutical company which makes and distributes the medical abortion drugs mifepristone and misoprostol.

GenBioPro is a United States pharmaceutical company which makes and distributes a generic version of the medication abortion drug mifepristone.

References

  1. "How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine". Washington Post. Retrieved 2018-10-23.
  2. Rutherford, Fiona (2023-04-14). "Why you've never heard of the company behind the abortion pill". Los Angeles Times. Retrieved 2024-08-07.
  3. Seelye KQ (17 May 1994). "Accord opens way for abortion pill in U.S. in 2 years". The New York Times. p. A1. Archived from the original on 3 August 2016.
  4. 1 2 Simonds, Wendy; Ellertson, Charlotte; Springer, Kimberly; Winikoff, Beverly (20 March 1998). "Abortion, revised: participants in the U.S. clinical trials evaluate mifepristone" (Archive). Social Science & Medicine. The Stacks Reader. 46 (10): 1313–1323. doi:10.1016/S0277-9536(97)10063-6 . Retrieved June 13, 2024.
  5. "DANCO LABORATORIES LIMITED v. The Washington Post Company, Intervenor-Appellant. (2000)". Supreme Court, Appellate Division, First Department, New York. July 27, 2000. Retrieved June 13, 2024 via caselaw.findlaw.com.
  6. "ABORTION PILL'S U.S. SPONSOR SUING HUNGARIAN DRUG FIRM". Washington Post. 1997-06-12. ISSN   0190-8286 . Retrieved 2024-06-13.
  7. Kolata G (29 September 2000). "U.S. approves abortion pill; drug offers more privacy and could reshape debate". The New York Times. p. A1. Archived from the original on 4 August 2017.
  8. "Generic abortion pill manufacturer sues FDA in effort to preserve access" Sarah McCammon April 19, 2023 NPR https://www.npr.org/2023/04/19/1170806176/abortion-pill-mifepristone-supreme-court-fda-generic-genbiopro